Can Moderna Pull Off More Disruptive Innovation? Flu And RSV Shots Are Next Test

Analysts Skeptical About Taking On Established Players

 
• By Andrew McConaghie
The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine.
Moderna's long-term strategy is to combine its COVID=19, flu and RSV shots in one - but proving efficacy against competitors will be a challenge. • Source: JOSEPH PREZIOSO/AFP via Getty Images (JOSEPH PREZIOSO/AFP via Getty Images)

More from Business

More from Scrip